Hubbry Logo
Savior siblingSavior siblingMain
Open search
Savior sibling
Community hub
Savior sibling
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Savior sibling
Savior sibling
Savior sibling
View on Wikipedia
from Wikipedia

A savior baby, savior sibling, or donor baby is a child who is conceived in order to provide a stem cell, bone marrow, or other transplant to a sibling that is affected with a fatal disease, such as cancer or Fanconi anemia, that can best be treated by hematopoietic stem cell, or other transplant.

Introduction

[edit]

The savior sibling is conceived through in vitro fertilization. Fertilized zygotes are tested for genetic compatibility (human leukocyte antigen (HLA) typing), using preimplantation genetic diagnosis (PGD), and only zygotes that are compatible with the existing child are implanted. Zygotes are also tested to make sure they are free of the original genetic disease. The procedure is controversial.[1][2][3]

Indications

[edit]

A savior sibling may be the solution for any disease treated by hematopoietic stem cell transplantation. It is effective against genetically detectable (mostly monogenic) diseases, e.g. Fanconi anemia,[4] Diamond–Blackfan anemia[5] and β-thalassemia, in the ailing sibling, since the savior sibling can be selected to not have inherited the disease. The procedure may also be used in children with leukemia, and in such cases HLA match is the only requirement, and not exclusion of any other obvious genetic disorder.

Procedure

[edit]
8-cell human embryo, 3 days after fertilization
Further information: Preimplantation genetic diagnosis

Multiple embryos are created and preimplantation genetic diagnosis is used to detect and select ones that are free of a genetic disorder and that are also a HLA match for an existing sibling who requires a transplant. Upon birth, umbilical cord blood is taken and used for hematopoietic stem cell transplantation.

Bioethical concerns

[edit]

The conception of a child in order to save another raises ethical issues, the sick eldest child being doomed, unless a compatible brother or sister can treat them.

This ethical debate is reflected in the terminology used, with opponents insisting on the term "baby‐medicine" to underline the "instrumentalization of the human body".[6] For these opponents, PGD is considered "utilitarianism taken to the extreme", "human procreation is totally diverted for the benefit of the project of creating a human being whose main "mission" is to be a medicine. Project carrying a radical alienation of one's freedom since its conception is only desired because of its therapeutic potential. They have no other choice than to take on the status of reservoir of cells for their sick elder, subject to a project predetermined by others, in this case society, the medical profession and their own parents."[citation needed]

The Jérome Lejeune Foundation, like other religious associations, which is anti-abortion, against research on embryos, but not against assisted procreation, speaks of a "double sorting baby", because this child is the survivor of a double sorting: the 1st in relation to the disease, the 2nd, in relation to compatibility,[7] thus wanting to criticize the selection of a large number of "healthy" embryos and therefore the "interruption of the life" of future babies, and therefore a eugenic drift. Finally, these same opponents refuse the term "double hope baby", because it means the same practice as the expression "baby-medicine" – therefore the same criticisms apply.[citation needed]

Specialists prefer to use "child of double hope": first hope of the birth of a healthy child, second hope of curing the eldest child, "the fact of being wanted for another does not exclude being wanted at the same time." "conceiving a child in the hope that it can cure someone is not in itself immoral, provided that it is not conceived exclusively for this purpose. We can reasonably hope that parents who love their child to the point of trying everything to save him will know how to love for himself the one by whom their first child was saved."[citation needed]

In 2002 the National Consultative Ethics Committee (CCNE) was reserved, recalling the "risk of instrumentalization of the unborn child" and that the "selection of an embryo and the initiation of a child conceived only as a potential donor, and not primarily for himself, is not thinkable in view of the values that he has always defended." However, he puts things into perspective by indicating that "allowing a desired child to represent, moreover, a hope of recovery for his eldest, is an acceptable objective, if he is second." The Council of State questions: "The use of "double IPR" has remained exceptional (7 requests since the end of 2009). The hope offered to certain families in the face of suffering from an illness without a therapeutic solution seems not to have been fully satisfied. Therefore, it is not certain that the weight that double PGD places on the child resulting from it has found sufficient medical justification."[8]

French law rejects the concept of "medicine baby" but authorizes that of "double hope baby".[9] In 2009, the CCNE recalled its 2002 opinion "allowing a desired child to represent hope of recovery for their eldest is an acceptable objective if he is second." As the current law provides, this extreme possibility should only be reserved for couples who have a child suffering from an illness leading to death. A savior baby or savior sibling is a child who is conceived in order to provide a stem cell transplant to a sibling that is affected with a fatal disease, such as cancer or Fanconi anemia, that can best be treated by hematopoietic stem cell transplantation.[citation needed]

Ethical critics argue that this practice instrumentalizes these children in two ways: first, by having them for instrumental reasons rather than for their own sake, and second, by valuing them solely as a means to cure their sick sibling, potentially violating ethical principles like beneficence and nonmaleficence. Supporters, on the other hand, contend that parents' motives should not be condemned, and the key question is how savior siblings are treated after birth. They argue that the Kantian principle prohibiting the use of individuals solely as means to an end does not apply if the savior sibling is also treated as an end in itself. The willingness of parents to go to great lengths to conceive such a child may indicate their dedication to the welfare of all their children.[10]

Legality

[edit]
  • In the United Kingdom, the House of Lords has ruled that it is lawful to use modern reproductive techniques to create a savior sibling.[11]
  • In Victoria, Australia, use of PGD for HLA typing is reviewed by the Infertility Treatment Authority on a case-by-case basis.[1]
  • In Spain, the Cortes Generales approved the Assisted Reproduction Law in 2006, which authorizes preimplantation diagnosis for therapeutic purposes.[citation needed]
  • In France, the bioethics law of 7 July 2011 authorizes the practice of double PGD, going beyond the opinion of the Council of State and thus perpetuating a practice provisionally authorized by the bioethics law of August 2004, including the decree application published in the Official Journal of 23 December 2006.[12]
  • In Switzerland, the law on medically assisted reproduction prohibits pre-implantation genetic diagnosis (PGD) and "savior siblings".[13]

History

[edit]

Yury Verlinsky and collaborators described the first case in 2001:[14] that of Adam Nash, born 29 August 2000.[15]

Challenges and considerations

[edit]

Concerns regarding savior siblings revolve around potential physical and psychological harm. Physically, there are inherent risks associated with the medical technologies involved in conceiving savior siblings, such as in vitro fertilization (IVF), preimplantation genetic diagnosis (PGD), and hematopoietic stem cell (HSC) donation. These risks appear to be relatively low, with IVF being a routine procedure and limited short-term harm observed with PGD and HLA typing. The risks associated with HSC transplantation depend on the source of HSC and collection method, with generally low risks.

However, there is a concern about the possibility of a savior sibling being repeatedly asked to donate HSC, which could potentially harm the child. To address this, legal safeguards can be put in place to limit the number of HSC donations by a child donor.

Psychologically, it has been suggested that savior siblings might experience harm if they discover they were conceived primarily to be an HSC donor for their sick sibling. However, there is insufficient empirical evidence to support this claim. On the contrary, it can be argued that savior siblings may experience psychological benefits from knowing they contributed to helping their ailing sibling, regardless of the transplantation's success. The balance between potential psychological benefits and medical risks remains a subject of debate.

Past studies on pediatric sibling donors of HSC transplantations indicate that the experience varies. In cases of unsuccessful transplantations, some siblings may experience negative emotions, particularly if the failure is linked to the sick sibling's death. Proper information, parental care, emotional support, and attention can help mitigate any potential negative psychological impacts on child donors, including savior siblings. Overall, addressing these concerns involves careful consideration of both the physical and psychological well-being of savior siblings during the decision-making process and throughout their lives.[16]

[edit]

The novel My Sister's Keeper, later adapted into a film, is about a child who was born as a savior sibling to her sister Kate who is affected by acute promyelocytic leukemia.

In the British soap opera Emmerdale, Debbie Dingle gave birth to her son Jack, who would serve as a savior sibling to his older sister Sarah, who was suffering from Fanconi anemia.

On the popular American show CSI: Crime Scene Investigation, the episode "Harvest" deals with the reported abduction and later murder of a thirteen-year-old girl named Alycia who was later revealed to be a savior sibling for her brother Daniel.

In the American show Heroes, one of the protagonists, Mohinder Suresh, is revealed to have been conceived to cure his sister Shanti of a deadly disease known as the Shanti Virus, although he was ultimately born too late to save her life. His antibodies act as a cure for other patients with the disease throughout the show as well.

On Star Trek: Enterprise, the episode "Similitude" sees a clone created of Trip Tucker for the purpose of organ harvesting. "Sim" is born through the highly controversial use of an alien lifeform.

The novel Never Let Me Go, later adapted into a film, is centred around a dystopian future society where human clones are created and allowed to live to their teenage years before being used for organ harvesting. The films Parts: The Clonus Horror and The Island have a similar premise.

In the Grey's Anatomy episode "I Bet It Stung," the character Donna is a savior sibling to her older sister Reese.

In the 9-1-1 episode "Buck Begins", it is revealed that Evan "Buck" Buckley was conceived as a savior sibling for his older brother Daniel.

In the Korean drama The Penthouse, the character Anna is adopted by a Korean-American family to be a savior sibling to their son, Logan Lee, who was suffering from bone marrow cancer at the time.

In the light novels of Sword Art Online and their respective anime adaptations, the character Vassago Casals was born from an affair his Japanese father had with a Spanish woman he paid for sexual services. Although Vassago's mother desired to perform an abortion, his father convinced her not to go through with it, as his older son from his actual wife had a congenital kidney defect, hoping that the child could serve as a kidney donor.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Savior sibling

View on Grokipedia
from Grokipedia
A savior sibling is a child conceived via fertilization combined with to provide a (HLA)-matched donation, typically hematopoietic stem cells from blood, to treat a pre-existing afflicted with a life-threatening such as or . This selective process screens embryos to ensure they are unaffected by the donor 's condition and compatible for transplantation, enabling early intervention without later extraction risks to the donor. The practice originated in the late 1990s, with the landmark case of Adam Nash, born in 2000 to supply that successfully treated his sister's after multiple failed unrelated donor attempts. Despite demonstrated medical efficacy in select cases, including over 20 reported successful transplants by 2014, success rates per IVF cycle hover below 5% for disorders like due to stringent matching criteria—a 1 in 4 HLA compatibility chance compounded by disease-free requirements yielding roughly 1 in 16 viable embryos. Ethical debates persist, centering on allegations of commodifying the donor child as a , potential long-term psychological burdens from family expectations, and slippery slopes toward broader genetic selection, though empirical data on donor welfare remains sparse and does not conclusively indicate harm, while proponents emphasize parental imperatives to secure viable treatments amid limited unrelated donor options. Legally permissible in jurisdictions like the under certain regulatory frameworks, the procedure faces bans or restrictions elsewhere owing to these bioethical concerns, highlighting tensions between utilitarian life-saving outcomes and deontological protections of individual dignity.

Definition and Background

Definition and Terminology

A savior sibling is a child conceived through fertilization (IVF) combined with preimplantation to ensure the embryo is free of the afflicting an existing sibling and possesses (HLA) compatibility, allowing the newborn to serve as a donor of hematopoietic stem cells from umbilical cord blood, , or other tissues to treat the sibling's life-threatening condition. This selection process targets only the absence of the specific inherited disease and HLA matching, with a success rate for HLA compatibility in unrelated donors around 1 in 100,000 but approximately 25% among siblings. The term "savior sibling" emerged in public discourse around 2000 following the birth of Adam Nash on August 29, 2000, the first documented case where parents used IVF and (PGD) with HLA typing to create a donor for his sister Molly, who suffered from , a failure disorder. In medical literature, alternatives such as "HLA-matched sibling" or "tissue-typed donor sibling" are preferred to focus on the technical criteria of genetic screening for compatibility rather than anthropomorphic implications. This practice differs from "designer babies," where embryo selection might aim at non-therapeutic traits like physical appearance or , as savior selection is restricted to averting the donor's of the familial and achieving HLA congruence solely to enable transplantation for the affected , without broader genetic modifications or enhancements.

Medical Rationale and Context

The biological imperative for savior siblings stems from the critical role of human leukocyte antigen (HLA) compatibility in hematopoietic stem cell transplantation (HSCT), where mismatches trigger immune-mediated rejection or (GVHD), compromising engraftment and patient survival. Full siblings inherit HLA haplotypes from parents, yielding only a 25% probability of identical matching at key loci, as each child randomly receives one of four possible parental combinations. In scenarios requiring urgent HSCT for genetic bone marrow failure, this low natural odds ratio often precludes timely intervention, as alternative unrelated donors may not materialize. Savior sibling creation addresses this through embryo selection, enabling deterministic HLA matching alongside exclusion of the familial disease allele, which yields near-100% compatibility in selected embryos and markedly elevates transplant efficacy. HLA-identical sibling donors confer lower risks of acute GVHD (13% incidence of grade II-IV) and chronic GVHD (14%) compared to unrelated donors (25% and 26%, respectively), facilitating faster hematopoietic recovery and reduced infectious complications. Cord blood units from such matched siblings further mitigate GVHD relative to unrelated cord blood or marrow sources, as evidenced by multivariate analyses showing elevated GVHD hazards in non-sibling grafts. Empirical outcomes include the 2000 transplant of cord blood from Adam Nash to his sibling with Fanconi anemia, which achieved successful engraftment and reversal of bone marrow aplasia without severe GVHD. These advantages counter systemic gaps in unrelated donor registries, where ethnic underrepresentation—particularly among minorities—yields rates as low as 29-79% depending on ancestry, prolonging searches by months to years and exacerbating pre-transplant mortality, with thousands dying annually without viable donors. Such delays are causally linked to poorer in time-sensitive pediatric disorders, justifying selective creation as a targeted means to secure optimal donor tissue when registries fail.

Medical Indications and Applications

Targeted Diseases and Conditions

Savior siblings are selected primarily for conditions amenable to cure through (HSCT) using HLA-matched or , focusing on genetic disorders causing bone marrow failure or hemoglobinopathies where unrelated donors are unavailable or mismatched. Key indications include , β-thalassemia major, , and select pediatric leukemias requiring urgent HSCT, as these yield superior outcomes with sibling donors compared to unrelated or haploidentical sources. Fanconi anemia, an autosomal recessive disorder involving DNA repair defects leading to bone marrow failure, congenital malformations, and malignancy predisposition, has a global incidence of approximately 1 in 136,000 live births, with higher rates in Ashkenazi Jewish and Roma populations. In such cases, savior sibling-derived HSCT achieves engraftment and disease remission when no other match exists, averting progression to or . β-Thalassemia major, characterized by severe due to defective β-globin chain production requiring lifelong transfusions, affects an estimated 1 in 100,000 births worldwide for symptomatic cases, though carrier rates exceed 10% in Mediterranean, Middle Eastern, and Southeast Asian regions. HLA-matched sibling HSCT from cures transfusion dependence in over 80% of early-treated patients, making savior selection viable in endemic areas lacking donors. Sickle cell disease, an autosomal recessive causing vaso-occlusive crises and organ damage, impacts 70,000–100,000 individuals in the United States alone, with global prevalence exceeding 7 million cases predominantly in . Only severe phenotypes warrant HSCT, where matched sibling donors enable cure rates above 85%, particularly via to mitigate graft-versus-host risks. Certain leukemias, such as acute lymphoblastic or myeloid types in children, benefit from preimplantation HLA typing to select matched embryos for HSCT when the disease is non-heritable but requires immediate donor access post-remission. Matched sibling transplants reduce relapse and non-relapse mortality compared to alternatives, though this application lacks genetic disease avoidance via PGD. This approach is limited to HSCT-compatible conditions, excluding solid organ transplants needing post-infant donor size, as umbilical cord blood volumes suffice only for pediatric recipients under 40 kg.

Clinical Success Metrics

Clinical success in savior sibling procedures is primarily measured by the efficacy of (HSCT) using or from the HLA-matched donor , alongside the reproductive success of IVF cycles incorporating (PGD) for HLA typing and disease avoidance. For conditions like , 5-year overall survival rates following HSCT from an HLA-matched donor exceed 80%, reflecting improved engraftment and reduced transplant-related mortality compared to unrelated donors.00248-3/fulltext) Sibling donor transplants demonstrate lower rates of graft rejection and (GVHD), typically under 10% for acute rejection in matched cases, versus higher incidences (up to 20-30%) with unrelated donors due to HLA disparities. In beta-thalassemia major, HSCT from HLA-identical s achieves cure rates approaching 90% with sustained engraftment, as evidenced by cases where donor fully resolves transfusion dependence without relapse over multiple years. Complication profiles favor sibling matches, with non-relapse mortality below 15% in optimized protocols, attributed to precise HLA compatibility minimizing immune reactions. Aggregate data from multi-center analyses confirm that HLA-matched sibling HSCT yields overall survival superior to unrelated sources by 10-20 percentage points in pediatric genetic disorders. Reproductive outcomes for generating the donor sibling via PGD-HLA typing yield live birth rates of 25-35% per , comparable to standard IVF but requiring multiple cycles (average 1.9-2 per couple) due to the low probability (approximately 19%) of identifying an unaffected, HLA-matched per cycle. Implantation rates in these cycles range from 26-32%, with clinical rates around 35%, though overall per-cycle success remains under 10% owing to embryo selection stringency. Long-term follow-up data, though limited by the procedure's relative novelty, indicate durable remissions; for instance, a 2010 case resulted in full recovery for a with Diamond-Blackfan following transplant from her savior sibling, with no reported relapses over a . Similarly, a 2020 Indian case achieved cure of beta-thalassemia in the via donation from the engineered sibling, demonstrating scalability in diverse settings without elevated failure rates. These outcomes underscore efficacy without disproportionate complications, though broader registries report 70-80% of treated patients achieving long-term disease-free survival.

Procedure and Technology

In Vitro Fertilization and Preimplantation Genetic Diagnosis

In vitro fertilization (IVF) begins with controlled ovarian stimulation, where exogenous gonadotropins such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH) analogs are administered to recruit and mature multiple ovarian follicles over approximately 8-14 days, with progress monitored through transvaginal ultrasound and serum estradiol levels to prevent ovarian hyperstimulation syndrome. Egg retrieval is performed 34-36 hours after triggering final oocyte maturation with human chorionic gonadotropin (hCG) or a gonadotropin-releasing hormone (GnRH) agonist, involving ultrasound-guided transvaginal aspiration of follicular fluid containing mature oocytes. Retrieved oocytes are fertilized in the laboratory either through conventional insemination with prepared sperm or intracytoplasmic sperm injection (ICSI), yielding zygotes that are cultured in specialized media under controlled conditions to the blastocyst stage, typically reaching 5-6 days post-fertilization, where they consist of 100-200 cells with a distinct inner cell mass and trophectoderm. Preimplantation genetic diagnosis (PGD), reclassified as preimplantation genetic testing for monogenic/single-gene defects (PGT-M), integrates with IVF by performing a trophectoderm biopsy on day 5-6 blastocysts, extracting 5-10 cells from the outer layer destined to form the , minimizing impact on the that develops into the . These biopsied cells are subjected to (PCR)-based amplification followed by targeted genetic sequencing to identify the specific pathogenic mutation associated with the proband's condition, confirming the embryo's unaffected status for transplantation. Diagnostic protocols prioritize single-cell or few-cell analysis techniques validated for high fidelity, with error rates below 1% when using linked polymorphic markers to distinguish and reduce allele dropout risks. Advancements in next-generation sequencing (NGS) have elevated PGD reliability by enabling comprehensive detection and assessment in a single , achieving diagnostic accuracies exceeding 99% even in cases of potential mosaicism, where discordant cell lines within the embryo could otherwise confound results from earlier methods like (). NGS protocols mitigate mosaicism-related misdiagnosis by quantifying low-level or segmental imbalances across biopsied cells, with validation studies demonstrating concordance rates above 98% against post-implantation confirmatory testing, though residual limitations persist due to embryonic self-correction or sampling variability.

Human Leukocyte Antigen Matching and Selection

In savior sibling selection, (HLA) compatibility is determined through preimplantation of embryos, focusing on high-resolution allele-level typing at key loci to minimize immunological risks in subsequent (HSCT). The HLA system, part of the , encodes proteins essential for immune recognition; mismatches trigger T-cell mediated (GVHD) or rejection via alloreactive responses against foreign antigens. Standard typing targets HLA-A, -B, -C (class I loci), and -DRB1, -DQB1 (class II loci), evaluating 10 alleles for a full match, with HLA-DPB1 sometimes included for enhanced precision (12/12 match), as these loci account for the majority of transplant outcomes influenced by disparities. This typing integrates with (PGD) by biopsying embryonic cells (typically at the stage via trophectoderm) to extract DNA, which is then sequenced and compared against the affected sibling's established HLA profile. Embryos unaffected by the target genetic disease—confirmed via -specific PCR—are further assessed for HLA inheritance; only those achieving at least 10/10 identity across the core loci are selected for uterine transfer, while non-compatible embryos are discarded to optimize donor viability. phasing, often linked to the disease-causing on the same , facilitates accurate prediction of compatibility without requiring full parental typing in all cases, enabling selection rates aligned with Mendelian probabilities (25% for full sibling matches). Empirical data validate this approach: HLA-identical donors yield superior engraftment and reduced GVHD compared to unrelated or mismatched sources, with cumulative incidence of grade II-IV acute GVHD typically 20-30% in matched HSCT versus over 40% in alternative donors, and severe (grade III-IV) cases often under 10% due to minimized alloreactivity. In cohorts of HSCT from PGD-selected HLA-matched siblings, such as 44 reported pediatric cases, outcomes mirrored those of naturally conceived identical donors, with low GVHD rates (e.g., <5% severe acute in optimized protocols) and high overall survival, underscoring the causal role of allelic identity in suppressing donor T-cell attacks on host tissues.

Historical Development

Conceptual Origins and Early Proposals

The concept of selecting embryos via preimplantation genetic diagnosis (PGD) to produce an HLA-matched sibling donor emerged in the 1990s as a theoretical extension of PGD techniques, initially developed in 1990 for screening single-gene disorders like cystic fibrosis and avoiding X-linked conditions through sex selection. This built on foundational work in IVF and embryo biopsy, enabling genetic analysis at the 8-cell stage to identify unaffected embryos for transfer, thereby preventing disease transmission without the need for post-implantation termination. Parallel advances in transplant biology provided the rationale: the first successful unrelated umbilical cord blood stem cell transplant in 1988 for Fanconi anemia demonstrated high efficacy with HLA-matched donors, where full matches minimize rejection risks via shared antigens on chromosome 6. Siblings inherit HLA haplotypes from parents with a 25% probability of identical matching—1/4 chance both haplotypes align—far superior to unrelated donors (probability ~1 in 10,000), prompting first-principles consideration of targeted selection to bypass registry limitations and expedite life-saving cord blood or marrow donation. By the late 1990s, researchers including Yury Verlinsky proposed combining PGD for monogenic diseases with HLA genotyping, using polymerase chain reaction on biopsied cells to assess compatibility alongside disease status, thus framing the approach as disease prevention with incidental donor benefit rather than primary utility creation. Early discussions in reproductive genetics literature, such as those anticipating technical feasibility in journals like Human Reproduction, emphasized empirical grounding in transplant success rates (e.g., >90% engraftment with matched siblings) over speculative , positioning it as a causal extension of avoiding heritable harm while leveraging known genetics. These pre-2000 conceptualizations avoided hype, focusing on verifiable PGD accuracy (~95% for single loci) and HLA's role in graft survival, without yet addressing implementation challenges like multi-locus typing efficiency.

Landmark Cases from 2000 Onward

The first documented savior sibling case occurred in the United States in 2000, when Adam Nash was born on August 29 to parents Jack and Lisa Nash via in vitro fertilization (IVF) combined with (PGD) for (HLA) matching and to ensure he was free of , the condition afflicting his six-year-old sister Molly. Molly, diagnosed with the rare inherited blood disorder that impairs function and increases cancer risk, received an umbilical cord blood transplant from Adam shortly after his birth; follow-up tests confirmed the procedure's success in eradicating her disease. Adam, now an adult, has remained healthy without the genetic condition or reported long-term complications from the donation process. In the , the first complete savior sibling procedure—from embryo selection to successful transplant—took place in 2010, involving nine-year-old Megan Matthews from , who suffered from leading to bone marrow failure and infection vulnerability. Her 18-month-old brother Max was conceived through IVF and PGD to match her HLA type while being unaffected by the disease; tissue donated by Max enabled a transplant that successfully treated Megan, marking the UK's initial proof-of-concept for the full protocol under regulated conditions. The case demonstrated procedural viability in a jurisdiction with prior selection allowances but newly applied to tissue donation. France reported its inaugural savior sibling birth in January 2011, when Umut Talha was delivered to Turkish-origin parents whose older children had beta-, a genetic blood disorder requiring frequent transfusions. Selected via PGD for HLA compatibility and absence of the thalassemia mutation—termed a "double-hope" outcome—Umut's blood was used to treat his siblings, providing of in a country previously restrictive on such selections despite advancing IVF technologies. These early cases, building on the Nash precedent, contributed to over a hundred documented instances by the mid-2010s, with high rates of transplant success and no widespread reports of donor failures, affirming the technique's reliability for HLA-matched interventions.

Global Expansion and Recent Instances (2010–2025)

In , the first documented savior sibling case occurred in 2018 when Kavya Solanki was conceived via IVF and (PGD) combined with (HLA) matching to treat her brother Abhijeet's beta-thalassemia major, a condition requiring lifelong transfusions; her transplant in early 2020 successfully alleviated his symptoms, marking a in South Asian applications despite regulatory ambiguities. Similar procedures have proliferated sporadically in , with reporting leadership in cord blood transplants from savior siblings for , leveraging established IVF infrastructure for HLA-compatible selections. In the and , cases include successful PGD-HLA procedures in for major, where a 2025 study of 16 families documented parental experiences with no reported procedural failures in donor matching or transplantation outcomes. The completed its inaugural full-cycle savior sibling process in 2010, culminating in a stem cell transplant for , with subsequent approvals under the Human Fertilisation and Embryology Authority (HFEA) enabling ongoing use without interruption. Technological advancements, particularly the adoption of next-generation sequencing (NGS) in PGD since around 2015, have enhanced embryo screening accuracy for both genetic disorders and HLA compatibility, reducing false positives and enabling higher success rates per IVF cycle in compatible jurisdictions. As of 2025, savior sibling creation remains viable in permissive regions like the and , where clinics offer PGD-HLA routinely for conditions such as and anemias, though comprehensive outcome data for donors and recipients post-2021 is scarce due to privacy protections and lack of centralized tracking. No widespread procedural halts have occurred amid ethical scrutiny, with sustained demand reflected in clinic approvals and familial reports, underscoring adaptation to varied international regulations.

Ethical Debates

Utilitarian Arguments Supporting the Practice

From a utilitarian standpoint, the creation of savior siblings maximizes overall welfare by averting the premature death of an existing child afflicted with a life-threatening , such as , where untreated bone marrow failure leads to mortality in the majority of cases before age 10. (HSCT) from an HLA-matched sibling donor yields superior outcomes compared to unrelated donors, with empirical data indicating higher engraftment success and reduced complications, thereby preserving family utility through the proband's survival. The burdens imposed on the donor sibling are negligible, particularly when utilizing umbilical cord blood, a procedure that entails no risk or pain to the newborn as it involves collecting residual blood from the discarded post-delivery. Subsequent peripheral blood or harvests, if required, carry only transient side effects like fatigue or mild pain, with complication rates below 5% in pediatric donors and no long-term sequelae documented in follow-up studies. This asymmetry—certain life extension for one child versus minimal, reversible inconvenience for another—yields a clear net positive in hedonic , outweighing speculative psychological costs absent empirical verification. Parental reproductive autonomy further bolsters the utility, enabling families to select embryos via (PGD) and HLA typing to address the causal inevitability of inherited disease, consistent with precedents affirming liberty in selection for optimization. By empowering parents to mitigate foreseeable suffering in offspring, the practice enhances aggregate family well-being, as evidenced by qualitative reports of strengthened bonds and reduced parental grief post-successful transplantation. Longitudinal evidence from documented cases reinforces these benefits, with over 20 successful HSCTs from savior siblings reported by 2014, including the landmark 2000 birth of Adam Nash for and the UK's first fully domestic procedure in 2010, showing no adverse donor outcomes and proband survival into adolescence or beyond. These precedents demonstrate that actual utilities realized—familial cohesion and lives extended—eclipse hypothetical harms, particularly given the absence of verified long-term donor detriment in available pediatric HSCT cohorts.

Deontological and Rights-Based Criticisms

Critics from a deontological perspective contend that the creation of savior siblings inherently treats the prospective child as a mere instrument for alleviating the suffering of an existing sibling, contravening Immanuel Kant's categorical imperative that persons must never be used solely as means to others' ends but always as ends in themselves. This objection holds that preimplantation genetic diagnosis (PGD) combined with human leukocyte antigen (HLA) matching selects embryos based on their utility as potential donors of hematopoietic stem cells or other tissues, thereby subordinating the donor child's intrinsic dignity to parental or familial goals, regardless of any net benefits to the family unit. Rights-based arguments further assert that such selection undermines the donor child's , particularly under Article 3 of the Convention on the Rights of the Child (UNCRC), which mandates that the best interests of the child serve as a primary consideration in all actions concerning children. Ethicists argue this prioritizes the therapeutic needs of the afflicted over the donor's right to an unburdened existence free from predetermined roles, potentially imposing lifelong expectations of donation that erode personal and impose psychological pressures, such as around being a "." These concerns emphasize inherent wrongs in commodifying human life through , where embryos are screened and discarded not for their own defects but for failing to match donor criteria, echoing broader fears of reducing progeny to resources. A related deontological worry involves the toward non-therapeutic genetic selection, where therapeutic HLA matching could normalize embryo selection for traits beyond disease mitigation, facilitating a form of liberal that devalues lives incompatible with parental preferences. Critics, including those wary of historical eugenic abuses, caution that permitting savior sibling creation erodes absolute prohibitions on offspring, potentially expanding to enhancements like or physical attributes under the guise of family welfare, thus violating duties to respect human equality and natural procreative limits. While some frame this as a left-leaning concern over and exploitation of vulnerable , others from conservative viewpoints highlight it as a right-leaning alarm against hubristic interference in human dignity, akin to state-sanctioned programs of the early that sterilized or euthanized the "unfit." These positions maintain that the practice's moral permissibility cannot hinge on outcomes but on its intrinsic respect for each life as an irreplaceable end.

Empirical Evidence on Long-Term Outcomes for Donor Children

Limited empirical data exist on the long-term health outcomes of donor children conceived via (PGD) with (HLA) matching, as the practice has been in use for only about 25 years and involves relatively few cases worldwide. These children are genetically screened to exclude the familial affecting the , resulting in birth outcomes comparable to those of other PGD-conceived children, with no documented elevation in morbidity or mortality attributable to the HLA selection process itself. A collaborative multi-center European study reported 90 healthy HLA-compatible children born from such procedures, with a misdiagnosis rate of 1.1% leading to one non-identical HLA outcome, and no adverse health sequelae noted in follow-up. Similarly, clinical experience from over 50 centers documented 59 healthy HLA-compatible births, with successful transplants performed using donor material from these siblings without reports of donor-specific health complications. In the landmark case of Adam Nash, the first documented savior sibling born in 2000 via PGD-HLA , no public reports as of 2025 indicate developmental or health abnormalities; he provided that extended his sister's survival, and subsequent family accounts describe normal physical growth and absence of disease. Broader data from PGD-HLA cycles show live birth rates per transfer around 28-35%, with born children exhibiting standard health metrics for IVF offspring, including no increased incidence of congenital anomalies beyond baseline procedural risks mitigated by genetic selection. The absence of systematic health tracking registries limits comprehensive longitudinal analysis, but available case series spanning 2000-2018 reveal no patterns of elevated physical risks, as donors are inherently disease-free by design. Psychological outcomes for donor children remain understudied, with sample sizes typically below 50 and conflating effects of HLA conception, donation procedures, and dynamics. on pediatric donors (not exclusively saviors) indicate short-term elevations in anxiety and lower post-donation, alongside adaptive school behaviors, but these resolve without long-term deficits in most cases. A review of donor experiences in HSCT contexts noted moderate post-traumatic stress and self-esteem dips, yet attributed these more to the donation event than to knowledge of savior status. Specific to savior siblings, parental surveys over a decade post-procedure report neutral to positive integration, with 62% citing emotional benefits outweighing procedure-related stress, though donor children's direct self-reports are scarce. No large-scale evidence links savior conception causally to or identity harm; instead, small qualitative assessments suggest potential bonding benefits from saving a sibling, countering theoretical concerns amid 20+ years of practice without widespread reported psychological crises.

Regulations in the United States

In the United States, the creation of savior siblings via (PGD) for (HLA) matching lacks any federal prohibition, allowing the practice under professional guidelines for serious sibling conditions amenable to transplantation, such as or . The American Society for Reproductive Medicine (ASRM), a leading professional body, endorses PGD-HLA typing when no unrelated donor is available, the transplant can be delayed 9–12 months, and the maternal age supports IVF feasibility, with each embryo carrying a roughly 25% chance of full HLA compatibility to a .00582-3/fulltext) These guidelines, reflected in ASRM committee opinions since the early 2000s, emphasize case-by-case ethical review by clinicians rather than blanket restrictions. State-level regulations exhibit variance but remain largely permissive toward embryo selection for implantation, with no outright bans on PGD-HLA; however, some states like and restrict public funding or certain embryo research protocols, indirectly influencing clinic operations without targeting savior sibling selection specifically. Oversight falls primarily to professional self-regulation, as the (FDA) approves IVF-related devices and genetic tests but defers ethical and selection decisions to physicians and parents, absent federal mandates on reproductive genetic technologies. By the 2020s, U.S. clinics have conducted dozens of PGD-HLA cycles, comprising an estimated 1% of total PGD procedures annually, yielding successful donor matches in documented cases such as those involving Colorado-based IVF for patients. This decentralized approach has facilitated empirical outcomes like transplants from matched siblings, though success rates vary by clinic, with multiple IVF cycles often required due to the 25% matching probability per embryo.00582-3/fulltext)

Policies in the United Kingdom and Europe

In the , the Human Fertilisation and Embryology Authority (HFEA) regulates preimplantation tissue typing (PTT), a form of (PGD) combined with (HLA) matching, to create so-called savior siblings for treating serious conditions in existing children, such as certain blood disorders. PTT has been licensed by the HFEA since 2004, but only in cases where embryos are screened both for the genetic disease affecting the sibling and for HLA compatibility, ensuring the selected embryo is unaffected by the familial condition. The first complete savior sibling treatment conducted entirely within the UK occurred in 2010, when a one-year-old boy donated to his nine-year-old sister with a life-threatening blood disorder, following IVF and embryo selection licensed by the HFEA. European policies on savior siblings exhibit significant variation, reflecting national differences in PGD regulations. In , PTT for HLA matching was theoretically permitted under the 2004 Bioethics Law since 2006, with the country's first such birth occurring in 2011, involving a boy whose umbilical cord blood treated his sibling's genetic blood disease. By contrast, broadly prohibits PGD, including for HLA typing to create savior siblings, due to legal restrictions on embryo selection viewed as eugenic. Other nations, such as and , have permitted the practice for over a decade, with approvals tied to therapeutic necessity for severe sibling conditions. Across , approvals for savior sibling creation have trended toward therapeutic contexts since the early , with 13 of 15 Western European countries allowing PGD by the , though stringent oversight persists to limit non-medical uses. Into the , policies have shown stability, with no widespread expansions or reversals reported, maintaining focus on cases involving life-threatening sibling illnesses treatable via donation. This patchwork approach underscores national ethical divergences, with permissive frameworks in the UK and select others enabling practical implementation via licensed clinics, while prohibitive stances in countries like preclude it entirely.

International Variations and Restrictions

In , the creation of savior siblings via (PGD) combined with (HLA) typing is permitted under the (ICMR) guidelines for assisted reproductive technologies, which allow PGD for severe hereditary diseases but require ethical review to prevent misuse. A landmark case occurred in October 2020, when a girl named Kavya was born through IVF and PGD to serve as a donor for her five-year-old brother afflicted with beta-thalassemia major; the procedure screened embryos for the and HLA compatibility, marking India's first publicly reported instance despite ongoing debates over potential exploitation of the donor child. In , regulations under the Ministry of Health restrict clinical PGD primarily to monogenic disorders, permitting research on selection techniques but prohibiting routine HLA matching for savior siblings to avert eugenic risks and ensure welfare, with no verified clinical cases reported as of 2023; this stems from cultural emphases on familial alongside state controls on reproductive interventions to prevent social disparities. Australia maintains a prohibition on non-medical embryo selection, such as for sex preference or traits unrelated to health, yet explicitly permits PGD with HLA typing for savior siblings under state-level acts like Victoria's Assisted Reproductive Treatment Act 2008, subject to approval by bodies such as the Patient Review Panel to confirm medical necessity and minimize harm, reflecting a balance between disability avoidance and therapeutic imperatives. In Islamic countries, practices vary significantly due to differing interpretations of embryo status and ; Sunni-majority nations like often restrict or ban PGD for HLA matching based on views of embryos as possessing sanctity from conception, while Shia has issued fatwas permitting it for life-saving donations under therapeutic protocols since 2003, prioritizing familial salvation over early embryo rights. Malaysia's religious authorities similarly endorse savior siblings for Muslim families, arguing that 3- to 5-day embryos lack full and the procedure's benefits—such as —outweigh harms, provided no excess embryos are discarded wastefully. Globally, restrictions on savior siblings arise from cultural and religious valuations of , with outright prohibitions in nations emphasizing deontological protections—such as and —contrasting case-by-case allowances elsewhere; while no comprehensive (WHO) directive mandates uniformity, surveys of regulations indicate ethical trends toward conditional approvals for severe conditions, influenced by local rather than universal bans.

Risks and Challenges

Medical and Procedural Risks

The creation of savior siblings involves in vitro fertilization (IVF) combined with (PGD) for both disease allele screening and (HLA) typing, introducing specific procedural risks beyond standard IVF. (OHSS), a potential complication of ovarian stimulation in IVF, occurs in mild forms in 20-33% of cycles and moderate to severe forms in 3-6%, with severe cases requiring hospitalization in approximately 1% of stimulated cycles. biopsy for PGD, typically involving removal of 1-2 cells at the cleavage or stage, carries a misdiagnosis error rate of less than 1% per embryo based on validation studies, though mosaicism can contribute to discrepancies in up to 10% of cases in older cleavage-stage methods. Children born after PGD, including HLA-matched selections, exhibit no elevated rates of birth defects compared to those from conventional IVF, as evidenced by clinical outcome data. For the donor sibling, tissue procurement risks are minimized when using umbilical cord blood, which poses negligible harm as it is collected post-delivery without altering the birth process. In cases requiring subsequent harvest from the donor child, procedural risks include complications and temporary pain, but long-term adverse effects are rare in pediatric donors under medical supervision. HLA selection in PGD often necessitates discarding 70-80% of embryos due to non-matching or disease status, reflecting the low probability (approximately 1 in 4 for HLA compatibility among siblings, further reduced by disease screening), yet this does not correlate with increased anomalies in transferred embryos per meta-analyses of PGD outcomes. The recipient sibling (proband) faces risks from hematopoietic stem cell transplantation, including (GVHD), with acute GVHD occurring in up to 50% of HLA-matched sibling donor cases, though severe grades (III-IV) affect 10-20% and are manageable with immunosuppressive therapies. Chronic GVHD incidence ranges from 30-70% post-transplant, but advances in conditioning regimens and prophylaxis have improved mitigation, with overall transplant-related mortality decreasing in matched sibling settings. These biomedical hazards are quantifiable and addressed through standardized protocols, distinguishing them from unverified long-term concerns.

Psychological and Familial Impacts

Studies specifically examining the psychological impacts on savior siblings—children conceived via (PGD) to serve as (HLA)-matched donors—are scarce, as the practice emerged in the early , limiting long-term longitudinal data. Available draws from analogous on donors in pediatric transplants (BMT), where donors displayed elevated anxiety levels, reduced , and enhanced school adaptation skills relative to non-donor siblings, with approximately one-third of both groups reporting moderate post-traumatic stress symptoms. These findings indicate targeted psychological vulnerabilities but also adaptive strengths, without of pervasive long-term dysfunction; family support has been identified as a key mitigator of identity-related concerns in donor children. Concerns over savior siblings experiencing resentment or instrumentalization—such as feeling valued solely for their genetic —predominantly rely on theoretical rather than verified outcomes, with no empirical studies confirming causal harm from the selection process itself. In small cohorts of families with PGD-conceived donors, children remained healthy and, in reported cases, expressed pride in their role, suggesting resilience bolstered by open family communication. Familial dynamics in these households often strengthen post-transplant success, as the resolution of the proband's life-threatening condition fosters cohesion and , outweighing isolated instances of tension. among siblings appears rare and uncorrelated with PGD selection, attributable instead to general stressors of chronic illness families rather than donor status. Parents endure emotional strain from IVF and PGD cycles, including moral deliberations over selection, yet report minimal regret (e.g., scores of 3.0–13.25 on a 0–100 scale) and net psychosocial gains from the affected child's survival, with 14 of 17 surveyed parents willing to repeat the process. This relief typically enhances overall well-being, though extended family intrusions can exacerbate stress in some cultural contexts.

Societal Reception and Impact

Public Opinion and Polling Data

Public opinion surveys in the United States have consistently shown majority support for (PGD) combined with (HLA) typing to create a savior sibling for life-saving transplants, particularly when the procedure addresses severe, fatal genetic conditions. A national poll by the and Public Policy Center at found that 55% of respondents supported using PGD to select an embryo that is a tissue match for an ill sibling, with support rising to 60% for avoiding genetic diseases generally.00516-4/fulltext) This approval reflects a pragmatic prioritization of empirical benefits, such as potential cures for conditions like , over abstract ethical concerns in scenarios where alternatives like unrelated donors fail. In the , the Human Fertilisation and Embryology Authority (HFEA) consultations and policy shifts indicate regulated , with public input favoring case-by-case licensing for HLA typing since 2004, following initial restrictions. While comprehensive nationwide polls are limited, HFEA's review processes incorporated stakeholder views showing majority endorsement for therapeutic uses under oversight, avoiding non-medical selections. Opposition tends to cluster among religious groups, such as Catholics, where surveys highlight concerns over selection and discard rates, with up to 40% dissent linked to doctrines viewing embryos as possessing full moral status from conception. Support levels increase with severity, as evidenced by higher acceptance (over 70%) for fatal pediatric disorders in broader PGD attitude studies. Trends through 2025 remain stable in Western contexts, with steady 55-70% approval in U.S. polls for HLA-matched selections tied to verifiable medical need, undiminished by media portrayals but bolstered by high-profile successes like the 2000 Nash case.00516-4/fulltext) Emerging surveys in regions like report 62% support under regulations, driven by case awareness, though ethical qualms about child commodification persist at 38%. These patterns underscore favoring outcomes over deontological prohibitions, with divides primarily along rather than demographics.

Influence on Broader Reproductive Technologies

The concept of savior siblings, involving (PGD) coupled with (HLA) , has spurred refinements in PGD protocols, enhancing their precision for selecting embryos compatible with an affected sibling's needs while avoiding genetic disorders. This application, first successfully implemented in 2000 for treatment, demonstrated the viability of combining genetic screening with histocompatibility matching, leading to iterative improvements in biopsy techniques and genetic analysis that benefit broader PGD uses, such as aneuploidy screening in IVF cycles. However, savior sibling procedures remain a minor subset of overall PGD activity; for example, European Society of Human Reproduction and Embryology data from the early 2010s reported only 225 cycles involving HLA typing alongside disease exclusion, compared to thousands of annual PGD cycles for monogenic disorders or chromosomal abnormalities. Regulatory developments prompted by savior sibling cases have influenced frameworks for therapeutic embryo selection globally. In the , advocacy following early U.S. successes culminated in the Human Fertilisation and Embryology Authority (HFEA) granting the first license for PGD-HLA in 2004, which informed amendments in the Human Fertilisation and Embryology Act 2008 permitting only when linked to treating a serious condition in an existing child, subject to welfare assessments. This established a for narrowly defined exceptions in embryo selection, contrasting with outright bans in countries like and , and encouraged similar therapeutic carve-outs elsewhere, such as in and , where policies evolved to prioritize life-saving applications over non-medical trait selection. Looking ahead, the empirical track record of savior sibling outcomes— with over 40 successful hematopoietic stem cell transplants reported by 2014, albeit with per-cycle live birth rates below 5% for challenging conditions—supports measured advancement toward embryo gene editing technologies like CRISPR-Cas9 for HLA modification or disease correction. Unlike speculative non-therapeutic enhancements, the constrained, evidence-based deployment of PGD-HLA has not precipitated widespread expansion into cosmetic genetics, as regulatory emphasis on medical necessity and low procedural volumes indicate inherent limits rather than a trajectory toward unregulated "designer" reproduction. This history underscores potential for targeted editing in embryos to directly generate compatible donors, though current germline editing remains prohibited in clinical practice due to unproven long-term safety.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC8079567/
  2. https://www.nature.com/scitable/forums/genetics-generation/case-study-in-savior-siblings-104229158/
  3. https://pubmed.ncbi.nlm.nih.gov/25674777/
  4. https://journalofethics.ama-assn.org/article/shared-decision-making-about-ivf-savior-siblings/2014-01
  5. https://philarchive.org/archive/ALTASS-2
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC6220490/
  7. https://haematologica.org/article/view/6259
  8. https://www.cbsnews.com/news/a-genetically-screened-baby-saved-the-life-of-his-sister/
  9. https://www.emorywheel.com/savior-siblings-a-battle-between-ethics-or-saving-lives/
  10. https://scholarlycommons.law.wlu.edu/cgi/viewcontent.cgi?referer=&httpsredir=1&article=1456&context=crsj
  11. https://www.giftoflife.org/posts/post/what-is-the-chance-of-siblings-being-a-stem-cell-or-bone-marrow-match
  12. https://www.sciencedirect.com/science/article/pii/S1083879115006187
  13. https://haematologica.org/article/view/7379
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3890239/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC1173444/
  16. https://ij.org/bonemarrowstatistics/
  17. https://whyy.org/articles/cancer-patients-of-color-are-less-likely-to-be-matched-to-bone-marrow-donors/
  18. https://www.dkms.org/get-involved/stories/why-diversity-is-essential
  19. https://www.nature.com/articles/gim2014206
  20. https://www.ncbi.nlm.nih.gov/books/NBK1426/
  21. https://rarediseases.org/rare-diseases/fanconi-anemia/
  22. https://www.orpha.net/en/disease/detail/231214
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3510373/
  24. https://www.hematology.org/education/patients/anemia/sickle-cell-disease
  25. https://www.who.int/news-room/fact-sheets/detail/sickle-cell-disease
  26. https://www.ncbi.nlm.nih.gov/books/NBK538515/
  27. https://www.astctjournal.org/article/S1083-8791%2817%2930270-7/fulltext
  28. https://www.nature.com/articles/s41409-023-01997-3
  29. https://parentsguidecordblood.org/en/news/creating-savior-child
  30. https://www.nature.com/articles/s41423-021-00640-9
  31. https://parentsguidecordblood.org/en/news/thailand-leads-world-conceiving-savior-siblings-cord-blood-transplants-cure-thalassemia
  32. https://scholarship.kentlaw.iit.edu/cgi/viewcontent.cgi?article=4345&context=cklawreview
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4420220/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC4017834/
  35. https://academic.oup.com/humrep/article/33/3/520/4844073
  36. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/j.1600-0412.2012.01426.x
  37. https://www.theguardian.com/society/2010/dec/21/girl-first-ivf-saviour-sibling
  38. https://www.bbc.co.uk/news/world-asia-india-54658007
  39. https://onlinelibrary.wiley.com/doi/10.1007/s10897-013-9591-5
  40. https://www.ncbi.nlm.nih.gov/books/NBK562266/
  41. https://medlineplus.gov/ency/article/007279.htm
  42. https://www.urmc.rochester.edu/strong-fertility-center/services/infertility/infertility-treatment-options/ivf/ivf-step-by-step
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC11236403/
  44. https://www.sciencedirect.com/science/article/abs/pii/S1521693424000725
  45. https://academic.oup.com/humrep/article/33/7/1342/5001645
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC12077728/
  47. https://www.fertstert.org/article/S0015-0282%2821%2901796-9/fulltext
  48. https://www.researchgate.net/publication/226998735_%27Saviour_Siblings%27_The_Distinction_between_PGD_with_HLA_Tissue_Typing_and_Preimplantation_HLA_Tissue_Typing
  49. https://haematologica.org/article/view/7733
  50. https://pubmed.ncbi.nlm.nih.gov/28687174/
  51. https://www.sciencedirect.com/science/article/pii/S1083879118301587
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC9726707/
  53. https://www.astctjournal.org/article/S1083-8791%2815%2901922-9/fulltext
  54. https://www.rbmojournal.com/article/S1472-6483%2814%2900308-3/fulltext
  55. https://www.sciencedirect.com/science/article/abs/pii/S0301211509002449
  56. https://pubmed.ncbi.nlm.nih.gov/19411132/
  57. https://jamanetwork.com/journals/jama/fullarticle/193944
  58. https://www.lidsen.com/journals/genetics/genetics-03-03-084
  59. https://rgiscience.com/our-founder/
  60. https://www.rbmojournal.com/article/S1472-6483%2810%2962132-3/fulltext
  61. https://pubmed.ncbi.nlm.nih.gov/15126435/
  62. https://twin-cities.umn.edu/news-events/almost-two-decades-later-doctor-reflects-using-embryo-selection-save-young-girls-life
  63. https://www.bbc.com/news/health-12055034
  64. https://www.telegraph.co.uk/news/health/news/8217978/First-complete-saviour-sibling-transplant-carried-out-in-the-UK.html
  65. https://www.france24.com/en/20110208-france-first-saviour-baby-donor-biotechnology-stem-cell-research-clamart-umut-fryman
  66. https://healthcare-in-europe.com/en/news/france-the-country-s-first-saviour-sibling-is-a-double-hope-baby
  67. https://www.researchgate.net/publication/345093694_Saviour_Siblings_-_Current_Overview_Dilemmas_and_Possible_Solutions
  68. https://www.bbc.com/news/world-asia-india-54658007
  69. https://timesofindia.indiatimes.com/home/sunday-times/meet-kavya-indias-first-saviour-sibling/articleshow/78676267.cms
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC11869153/
  71. https://www.progress.org.uk/first-saviour-sibling-stem-cell-transplant-performed-in-uk/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC8812395/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC4603858/
  74. https://www.hfea.gov.uk/treatments/embryo-testing-and-treatments-for-disease/pre-implantation-tissue-typing-ptt/
  75. https://veriarch.com/missing-data-saviour-siblings
  76. https://www.ncbi.nlm.nih.gov/books/NBK559133/
  77. https://childrenscancer.org/camerons-story-surviving-fanconi-anemia/
  78. https://my.clevelandclinic.org/health/treatments/23981-cord-blood-banking
  79. https://www.nmdp.org/en/get-involved/join-the-registry/donate-cord-blood/cord-blood-donation-process
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC5897957/
  81. https://www.sciencedirect.com/science/article/abs/pii/S1472648310602751
  82. https://scholarship.shu.edu/cgi/viewcontent.cgi?article=1432&context=student_scholarship
  83. https://philpapers.org/rec/HENRIU-4
  84. https://www.rbmojournal.com/article/S1472-6483%2810%2960935-2/pdf
  85. https://academic.oup.com/humrep/article/17/3/534/642143
  86. https://www.wlu.edu/mudd-center/mudd-undergraduate-journal-of-ethics/volume-10-spring-2025/spare-parts-or-saviour-sibling-the-birth-of-an-ethical-dilemma
  87. https://digitalcommons.cedarville.edu/cgi/viewcontent.cgi?article=1029&context=bioethics_in_faith_and_practice
  88. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2969089-2/fulltext
  89. https://link.springer.com/chapter/10.1007/978-981-96-6779-6_8
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC11143109/
  91. https://www.rbmojournal.com/article/S1472-6483%2814%2900582-3/fulltext
  92. https://www.sciencedirect.com/science/article/abs/pii/S1472648311003245
  93. https://pubmed.ncbi.nlm.nih.gov/10516671/
  94. https://www.asrm.org/practice-guidance/practice-committee-documents/indications-and-management-of-preimplantation-genetic-testing-for-monogenic-conditions-a-committee-opinion-2023/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC7197420/
  96. https://www.invitra.com/en/savior-sibling/
  97. https://www.progress.org.uk/hfea-allow-pgd-for-hla-tissue-typing/
  98. https://www.jstor.org/stable/48711938
  99. https://healthcare-in-europe.com/media/issue/248/issue.pdf
  100. https://www.drishtiias.com/daily-news-analysis/saviour-sibling
  101. https://rupkatha.com/V17/n2/v17n207g.pdf
  102. https://pubmed.ncbi.nlm.nih.gov/29396799/
  103. https://www.austlii.edu.au/au/journals/ELECD/2017/1700.pdf
  104. https://pubmed.ncbi.nlm.nih.gov/17571785/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC9530092/
  106. https://www.researchgate.net/publication/240481689_An_Islamic_Perspective_on_IVF_and_PGD_with_Particular_Reference_to_Zain_Hashmi_and_Other_Similar_Cases
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC5373266/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4930775/
  109. https://pubmed.ncbi.nlm.nih.gov/15617721/
  110. https://publications.aap.org/pediatrics/article/125/2/392/72261/Children-as-Hematopoietic-Stem-Cell-Donors
  111. https://www.ncbi.nlm.nih.gov/books/NBK538235/
  112. https://www.sciencedirect.com/science/article/abs/pii/S1473050220300306
  113. https://eprints.hud.ac.uk/id/eprint/5438/1/BlythCreating.pdf
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC4429433/
  115. https://www.progress.org.uk/licensing-saviour-siblings-why-the-hfea-is-right/
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC2579414/
  117. https://www.tandfonline.com/doi/full/10.1080/14636778.2013.788358
  118. https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791%2820%2930119-1
  119. https://www.statnews.com/2019/09/16/could-editing-the-dna-of-embryos-with-crispr-help-save-people-who-are-already-alive/
Add your contribution
Related Hubs
User Avatar
No comments yet.